We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ALQ:ASXALS Ltd. Analysis

Data as of 2026-03-14 - not real-time

A$21.63

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

ALS Limited trades at AUD 21.63, comfortably above its 20‑day (24.18) and 50‑day (23.85) moving averages but just above the 200‑day SMA (20.70), indicating a longer‑term bullish bias. Technical signals are mixed: the RSI sits at 30.1, suggesting the stock is approaching oversold territory, while the MACD histogram is negative and the MACD line sits below its signal, flagging short‑term bearish momentum. Volume is on an increasing trend, supporting the price move, yet the 30‑day volatility is high at 35.6%, implying sizable price swings. Fundamentally, the company posts solid revenue growth (13.3%) and respectable margins, but a PE of 39.3 versus an industry average of 29.1 points to a premium valuation, reinforced by a DCF fair value of only AUD 6.15. Debt levels are elevated (debt‑to‑equity ≈ 104%) and the payout ratio is 70.6%, raising questions about dividend sustainability. The market sentiment is in “greed” mode (fear‑greed index 72.9), and analysts collectively rate the stock as a “buy” with a mean target of AUD 23.9, implying modest upside (~10%).
Overall, ALS offers strong global diversification and cash‑flow generation, but the combination of high leverage, overvalued multiples, and volatile price action suggests caution. Investors should weigh the near‑term technical downside risk against the company’s long‑term growth prospects and dividend appeal.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering just above support at 21.57
  • RSI near oversold levels (30) suggesting potential bounce
  • Bearish MACD histogram indicating continued downside pressure

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Revenue growth of 13.3% and solid operating margins
  • PE substantially above industry average, implying limited upside
  • High debt‑to‑equity ratio and elevated dividend payout ratio

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Diversified geographic footprint across multiple continents
  • Stable operating and free cash flow supporting dividend continuity
  • Overvaluation relative to DCF fair value and peers, requiring price correction

Key Metrics & Analysis

Financial Health

Revenue Growth13.30%
Profit Margin8.49%
P/E Ratio39.3
ROE19.36%
ROA8.19%
Debt/Equity104.36
P/B Ratio6.4
Op. Cash FlowA$439.2M
Free Cash FlowA$196.6M
Industry P/E29.1

Technical Analysis

TrendBullish
RSI30.1
SupportA$21.57
ResistanceA$26.17
MA 20A$24.18
MA 50A$23.85
MA 200A$20.70
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair ValueA$6.15
Target PriceA$23.92
Upside/Downside10.60%
GradeOvervalued
TypeBlend
Dividend Yield1.79%

Risk Assessment

Beta0.40
Volatility35.56%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.